Assistant Director, Division of Fiscal Management, Department for Medicaid Services
Key decision makers in the same organization
Organization Signals
Public Activity & Signals
Board meetings, strategic plans, and buyer signals from Rachel M. Barczak Reeves’s organization
Apr 21, 2026·BoardMeeting
Board
Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Advisory Committee Recommendations
The Pharmacy and Therapeutics Advisory Committee meeting focused on reviewing several new products to market, establishing initial and renewal approval criteria for drugs including Palsonify, Voyxact, Attruby, Redemplo, Forzinity, Aqvesme, Pivya, Zycubo, Cardamyst, and Myqorzo. Additionally, the committee discussed existing product guidance for Itvisma and recommendations regarding the preferred agent selection process for various therapeutic classes, including Bone Resorption Suppression, DPP-4 Inhibitors, GLP-1 Receptor Agonists, Colony Stimulating Factors, and Topical Steroids. A consent agenda was also reviewed with no recommended changes to the current Preferred Drug List status for a variety of classes.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The meeting addressed concerns regarding the modernization of the level of care processes and the requirement for Level of Care applications to be completed prior to admission to skilled nursing facilities. Participants discussed potential negative impacts on acute care discharge planning and SNF admissions, noting that the new process could cause delays and create barriers for patient transfers. There was a significant focus on the need for better communication with hospital partners to ensure they are aware of and prepared for these procedural changes. Additionally, the committee discussed compliance with federal PASAR requirements and the possibility of exploring different approaches used in other states to enhance the system and improve the efficiency of the admission process.
Oct 17, 2024·BoardMeeting
Board
Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Committee Recommendations
The committee provided official recommendations regarding new pharmaceutical products entering the market, outlining approval criteria, quantity limits, and duration for medications such as Tryvio, Iqirvo, Xolremdi, Vafseo, and Ohtuvayre. Furthermore, the committee established guidelines for numerous therapeutic drug classes, including Muscular Dystrophy agents, stimulants, antimigraine agents, growth hormones, and various dermatological and ophthalmic treatments, specifically addressing preferred drug list status and prior authorization requirements. A consent agenda was also addressed, confirming that several therapeutic classes will remain unchanged on the currently posted Preferred Drug List.
Apr 18, 2024·BoardMeeting
Board
Kentucky Department For Medicaid Services Pharmacy And Therapeutics Advisory Committee Committee Recommendations
The committee reviewed and made recommendations for several new products to market, establishing approval criteria, quantity limits, and age restrictions for medications including Voquezna, Voquezna Dual Pak, Voquezna Triple Pak, Fabhalta, Jesduvroq, Wainua, Agamree, and Zilbrysq. The committee also provided recommendations regarding the selection of preferred agents for various therapeutic classes, such as Non-Steroidal Anti-Inflammatory Drugs, Antihyperuricemics, Erythropoiesis Stimulating Proteins, Steroids, Pancreatic Enzymes, and Colony Stimulating Factors. Additionally, the committee reviewed a consent agenda for numerous other therapeutic classes and found no recommended changes to the currently posted Preferred Drug List.
Extracted from official board minutes, strategic plans, and video transcripts.
